僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Volociximab （M200） is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 （EC50=0.2 nM）. Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells （HUVECs）